RxDoctor Payments Data

Phil Alabata, DO

Glaucoma Specialist · Crestview, FLNPI 1770547077

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 30.6% of the total. Reporting peaked in 2022 at $3,747 and has fallen 90.0% since, to $375 in 2025.

$6,691in general payments, 2019–2025

Across 85 payments — averaging $78.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$2K
  • Carl Zeiss Meditec, Inc.$1K
  • Alcon$1K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • AbbVie$428
  • Glaukos Corporation$194
  • plus $334 from 7 others

What the payments were for

  • Travel & lodging$1,54023%
  • Food & beverage$2,59739%
  • Education$2,51838%
  • Gifts$361%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,691 in reported general payments places this provider in the 70th percentile of 31 glaucoma specialist providers in Florida.

See all glaucoma specialist providers in Florida

Medicare billing

Part B allowed, 2024
$509,434
Medicare patients
1,059
Services billed
4,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost65$38,124
RocklatanNetarsudil Mesylat/Latanoprost44$34,865
SimbrinzaBrinzolamide/Brimonidine Tart67$22,937
CombiganBrimonidine Tartrate/Timolol61$21,532
RestasisCyclosporine13$17,282
Alphagan PBrimonidine Tartrate40$15,177
Prednisolone Acetate267$11,686
VyzultaLatanoprostene Bunod19$10,089
IlevroNepafenac23$8,677
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$7,970
Brimonidine Tartrate303$7,446
Latanoprost540$7,231
Bromfenac Sodium45$6,045
Cyclosporine12$6,042
MoxifloxacinMoxifloxacin Hcl188$5,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$428$92,115179 claims
Aerie Pharmaceuticals, Inc.Rocklatan$96$34,86544 claims
AlconSimbrinza$1,266$22,93767 claims
Bausch & Lomb Americas Inc.Vyzulta$77$10,08919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 31 glaucoma specialist providers in Florida.

Other glaucoma specialist in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →